Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 18/20 | 0.85 |
| ▸ | FNTB | P49356 | 16/20 | 0.85 |
| ▸ | PGGT1B | P53609 | 14/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31002996 | 1.00 | FNTA (0.85) | FNTAFNTBPGGT1BTDP1ICMT | |
| SCHEMBL17548973 | 0.92 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL29394726 | 0.92 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL16111812 | 0.92 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| Trifluoroacetic Acid SCHEMBL16112378 | 0.88 | FNTA (0.91) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL6772134 | 0.85 | FNTA (0.84) | FNTAFNTBPGGT1BTDP1TAS1R3 | |
| SCHEMBL10018886 | 0.84 | FNTA (0.66) | FNTAFNTBPGGT1BTDP1TAS1R3 | |
| SCHEMBL6776503 | 0.84 | FNTA (0.85) | FNTAFNTBPGGT1BTDP1TAS1R3 | |
| SCHEMBL6776500 | 0.84 | FNTA (0.85) | FNTAFNTBPGGT1BTDP1TAS1R3 | |
| SCHEMBL14169146 | 0.81 | FNTA (0.87) | FNTAFNTBPGGT1BICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | FNTA 1114/4885FNTB 1259/4885PGGT1B 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.